Dipexium Announces Top-line Data from OneStep Phase 3 Trials with Locilex® in Mild Diabetic Foot Infection Did Not Meet Primary Clinical Endpoint of Superiority Versus Vehicle Plus Standardized Wound
Go back to Dipexium Announces Top-line Data from OneStep Phase 3 Trials with Locilex® in Mild Diabetic Foot Infection Did Not Meet Primary Clinical Endpoint of Superiority Versus Vehicle Plus Standardized Wound| DIPEXIUM PHARMACEUT (NASDAQ: DPRX) | Delayed: 1.34 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.34 | 52 Week High | $17.75 | |||
| Open | $25.99 | 52 Week Low | $1.15 | |||
| Day High | $1.34 | P/E | N/A | |||
| Day Low | $1.34 | EPS | $0.00 | |||
| Volume | 51,816 | |||||
